Obesity and metabolic syndrome in kidney transplantation

Current Hypertension Reports

Volumn 15, Issue 3, 2013, Pages 215-223

  Laguardia, Heather ^a   Zhang, Rubin ^a  

^a Tulane Center for Abdominal Transplantation   (United States)

Author keywords

Belatacept; Body mass index; Calcineurin inhibitor; Cardiovascular disease; Chronic allograft nephropathy; Corticosteroids; Graft loss; Hypertension; Immunosuppressive therapy; Mammalian target of rapamycin (mTOR) inhibitor; Metabolic syndrome; New onset diabetes after transplant; Obesity; Patient survival; Renal transplantation

Indexed keywords

BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADVERSE OUTCOME; ANOREXIA; ARTICLE; BILE ACID SYNTHESIS; BODY WEIGHT; CAUSAL ATTRIBUTION; CAUSE OF DEATH; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIFICATION; CYTOTOXICITY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HEMODIALYSIS; HORMONE INHIBITION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCREASED APPETITE; INSULIN RELEASE; INSULIN SENSITIVITY; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; METABOLIC SYNDROME X; NAUSEA; NONHUMAN; OBESITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SODIUM RETENTION; SURGICAL RISK; SURVIVAL RATE; VASOCONSTRICTION; WEIGHT REDUCTION;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 84877820389     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0335-6     Document Type: Article

References (95)

1. Zhang R, Lia J, Morse S, et al. Kidney disease in the metabolic syndrome. Am J Med Sci. 2005;330(6):319-25.
2. Killackey M, Zhang R, Sparks K, et al. Challenges of abdominal organ transplant in obesity. South Med J. 2010;103(6):532-40.
3. Kambham N, Markowitz G, Valeri A, et al. Obesity related glomeruplopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498-509.
4. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167-74.
5. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16(7):2134-40.
6. Ninomiya T, Kiyohara Y, Kubo M, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis. 2006;48(3):383-91.
7. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278:817-22.
8. Mathier M, Ramanathan R. Impact of obesity and bariatric surgery on cardiovascular disease. Med Clin N Am. 2007;91:415-31.
9. Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-7.
10. Weinbrenner T, Schroder H, Escurriol V, et al. Circulating oxidized LDL is associated with increased waist circumference independent of body mass index in men and women. Am J Clin Nutr. 2006;83:30-5.
11. Bagby S. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol. 2004;15:2775-91.
12. Wisse B. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15:2792-800.
13. Kimura KA, Sugaya T, et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int. 2002;62:1623-37.
14. Safardis P, Ruilope L. Insulin resistance, hyperinsulinemia and renal injury: mechanisms and implications. Am J Nephrol. 2006;26:232-44.
15. Alexander MP, Patel TV, Farag YM, et al. Kidney Pathologic changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009;53:751-9.
16. Ceriello A, Motz E. is oxidative stress the pathologic mechanism underlying insulin resistance, diabetes, and cardiovascular disease: the common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24:816-23.
17. Perlstein T, Gerhard-Herman M, Kollemberg N, et al. Insulin induces renal vasodilation, increases plasma rennin acivity and sensitizes the renal vasculature to angiotensin receptor blockage in healthy subjects. J Am Soc Nephrol. 2007;18:944-51.
18. Morales E, Valero A, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319-27.
19. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9:S16-23.
20. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458-82.
21. Fleischmann EH, Bower JD, Salahudeen AK. Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J. 2001;47:74-81.
22. Friedman AN. Adiposity in dialysis: good or bad? Semin Dial. 2006;19:136-40.
23. Kalantar-Zadeh K, Block G, Humphreys MH, et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793-808.
24. Salahudeen AK. Obesity and survival on dialysis. Am J Kidney Dis. 2003;41:925-32.
25. Leavey SF, McCullough K, Hecking E, et al. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2001;16:2386-94.
26. Molnar MZ, Streja E, Kovesday CP, et al. Associations of body mass index and weight loss with mortality in transplant waitlisted maintenance of hemodialysis patients. Am J Transplant. 2011;11:725-36.
27. Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38:789-95.
28. Kalantar-Zadeh K, Kopple J. Malnutrition as a cause of morbidity and mortality in dialysis patients. In: Kopple J, Massry S, editors. Nutritional management of renal disease. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 2004.
29. Chung SH, Lindholm B, Lee HB. Is malnutrition an independent predictor of mortality in peritoneal dialysis patients? Nephrol Dial Transplant. 2003;18:2134-40.
30. Stenvinkel P, Barany P, Heimburger O, et al. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl. 2002;80:103-8.
31. Fung F, Sherrard DJ, Gillen DL, et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis. 2002;40:307-14.
32. Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42:864-81.
33. Chang S. Effects of body mass index at transplant on outcomes of kidney transplantation. Transplantation. 2007;84:981-7.
34. Meier-Kriesche H, Arndorfer J, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70-4.
35. •• Molnar MZ, Kovesdy CP, Musci I, et al. Higher recipient body mass index is associated with post-transplant delayed kidney graft function. Kidney Int. 2011;80:218-24. The authors analyzed a cohort of 11,836 kidney transplant recipients from the national database of DaVita dialysis patients and the national scientific registry of transplant recipients. They found that pre transplant BMI was independently associated with delayed graft function, which required dialysis support during the first week of kidney transplant surgery.
36. Marks W, Florence L, Chapman P, et al. Morbid obesity is not a contraindication to kidney transplantation. Am J Surg. 2004;187:635-8.
37. Massarweh N, Clayton J, Mangum C, et al. High body mass index and short- and long-term renal allograft survival in adults. Transplantation. 2005;80:1430-4.
38. Yamamoto S, Hanley E, Hahn A, et al. The impact of obesity in renal transplantation: an analysis of paired cadaver kidneys. Clin Transplant. 2002;16:252-6.
39. Glanton C, Kao T, Cruess D, et al. Impact of renal transplantation on survival in end-stage renal disease with elevated body mass index. Kid Int. 2003;63:647-53.
40. Friedman AN, Miskulin DC, Rosenberg IH, et al. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis. 2003;41:480-7.
41. Pelletier S, Maraschio M, Schaubel D, et al. Survival benefit of kidney and liver transplantation for obese patients on the waiting list. Clin Transplant 2003; 77-88.
42. DeMaria E, Carmody B. Perioperative management of special populations:obesity. Surg Clin N Am. 2005;85:1283-9.
43. Alexander J, Goodman H. Gastric bypass in chronic renal failure and renal transplant. Nutr Clin Pract. 2007;22:16-21.
44. Mandelbrot DA, Pavlakis M, Danovitch GM, et al. The Medical Evaluation of Living Kidney Donors: a survey of US transplant centers. Am J Transplant. 2007;7(10):2333-43.
45. 2 were more likely to have significant decrement in renal function as estimated by MDRD-GFR. They also noted a substantial risk of hypertension in obese donors compared to non-obese donors.
46. Heimbach J, Taler S, Prieto M, et al. Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am J Transplant. 2005;5:1057-64.
47. Espinoza R. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant Proc. 2006;38(3):888-9.
48. Patel S, Cassuto J. Minimizing morbidity of organ donation: analysis of factors for perioperative complications after living-donor nephrectomy in the United States. Transplantation. 2008;85(4):561-5.
49. Rizvi SA, Naqvi SA, Jawad F, et al. Living kidney donor follow-up in a dedicated clinic. Transplantation. 2005;79:1247-51.
50. Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med. 2009;360:459-69.
51. Tavakol MM, Vincenti FG, Assadi H, et al. Long-term renal functionand cardiovascular disease risk in obese kidney donors. Clin J Am Soc Nephrol. 2009;4:1230-8.
52. • Kovas AZ, Molnar MZ, Szeifert L, et al. Sleep Disorders, depressive symptoms and health related quality of life - a cross sectional comparison between kidney transplant recipients and waitlisted patients on maintenance dialysis. Nephrol Dial Transplant. 2011;26(3):1058-65. This was an observational cross-sectional study of 187 patients from nine dialysis centers examining whether there was any subjective improvement in quality of life between the waitlisted patients on dialysis and those who had received a renal transplant. They found that the patients who received renal transplantation had a significantly better quality of life in respect to sleep, energy, depression and general health perceptions.
53. 2 had a 20-40 % higher risk of death and graft failure.
54. Johnson CP, Gallagher-Lepak S, Zhu YR, et al. Factors influencing weight gain after renal transplantation. Transplantation. 1993;56:822-7.
55. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69:2227-43.
56. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk: a meta-analysis. Transplantation. 2010;89:1-14.
57. Gaber AO, Moore LW. Patterns of early weight change after renal transplantation. J Ren Nutr. 1996;6:21-5.
58. Demme R. Hypertension in kidney transplant patients. Graft. 2001;4:248-55.
59. Lo A. Immunospuression and metabolic syndrome in renal transplant recipients. Metab Syndr Relat Disord. 2004;2(4):263-73.
60. Sander M, Lyson T, Thomas GD, Victor RG. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens. 1996;9:121S-38.
61. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73:775-82.
62. Kobashigawa J, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63:331-8.
63. Dimeny E, Fellstrom B. Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction? Nephrol Dial Transplant. 1997;12:21-4.
64. Wissing K, Abramowicz D, Broeders N, et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation. 2000;70:464-72.
65. Locsey L, Asztalos L, Kincses Z, et al. The importance of obesity and hyperlipidemia in subjects with renal transplant. Int Urol Nephrol. 1998;30:767-75.
66. Miller L. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;1:807-18.
67. Kasiske B, Ballantyne CM. Cardiovascular risk factors associated with immunosuppression in renal transplantation. Transplant Rev. 2002;16:1-21.
68. Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor free regimens in cadaveric renal transplantation. Transplantation. 2004;77:1228-35.
69. Flechner S, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002;74:1070-8.
70. Montori VM, Basu A, Erwin PJ, et al. Post transplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25:583-92.
71. Ducloux D, Kazory A, Chalopin JM. Post transplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation. 2005;79:438-43.
72. Kasiske B, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178-85.
73. Pham PT, Danovitch GM, Pham PC. The medical management of the renal transplant recipient. In: Johnson RJ, Feehally J, editors. Comprehensive clinical nephrology. Philadelphia: Mosby; 2007. p. 1085.
74. Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with post transplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002;13:1347-80.
75. Van der Werf N, Kroese FG, Rozing J, et al. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev. 2007;23:169-83.
76. Hamer RA, Chow CL, Ong AC, et al. Polycystic kidney disease as a risk factor for post transplant diabetes mellitus following renal transplant. Kidney Int. 2005;67:714-20.
77. Reisaeter AV, Hartmann A. Risk factors and incidence of post transplant diabetes mellitus. Transplant Proc. 2001;33(5A suppl):8S.
78. Esmatjes E, Ricart MJ, Ferrer JP, et al. Cyclosporine's effect on insulin secretion in patients with kidney transplants. Transplantation. 1991;52:500-3.
79. Ost L, Tyden G, Fehrman I. Impaired glucose tolerance in cyclosporine prednisolone treated renal graft recipients. Transplantation. 1988;46:370-2.
80. Nam J, Mun JI, Kim SI, et al. Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation. 2001;71:1417-23.
81. Augustine JA. Use of sirolimus in solid organ transplantation. Drugs. 2007;67:369-291.
82. Nathaniel B, Cochetti P, Mysore S, et al. Association of metabolic syndrome with development of new-onset diabetes after transplant. Transplantation. 2010;90:861-6.
83. US Renal Data System, USRDS 2010 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010. p. 2010.
84. Israni A, Snyder J, Skeans M, et al. Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant. Transpl Int. 2012;25:748-75.
85. Adeseun GA, Rivera ME, Thota S, et al. Metabolic syndrome and coronary artery calcification in renal transplant recipients. Transplantation. 2008;86:728-32.
86. Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant. 2004;19:2307-12.
87. Oschatz E, Benesch T, Kodras K, et al. Changes of coronary calcification after kidney transplantation. Am J Kidney Dis. 2006;48:307-13.
88. De Vries A, Bakker S, van Son W, et al. Insulin resistance as a putative cause of chronic renal transplant dysfunction. Am J Kidney Dis. 2003;41:859-67.
89. Ewel C, Foegh M. Chronic graft rejection: accelerated transplant arteriosclerosis. Immunol Rev. 1993;134:21-31.
90. De Vries A, Bakker S, van Son W, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all components contribute equally. Am J Kidney Dis. 2004;4:1675-83.
91. Porrini E, Delgado P, Bigo C, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplant. Am J Kidney Dis. 2006;48:134-42.
92. • Soveri I, Abedini S, Holadaas H, et al. Graft loss risk in renal transplant recipients with metabolic syndrome: subgroup analyses of the ALERT trial. J Nephrol. 2012;25(2):245-25. This study challenged the traditional opinion and prior studies regarding metabolic syndrome as an independent risk for graft loss. Here the non-diabetic renal transplant patients enrolled in the ALERT trial were followed for 7-8 years. After adjustment for other known risk factors for renal graft loss, metabolic syndrome was no longer associated with increased risk of graft loss.
93. •• Larsen CP et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010;90:1528-35. This study included 493 patients from the BENEFIT and 347 from the BENEFIT-EXT trails. After 2 years, patients on biological co-stimulation blocker belatacept-based therapy had better renal function and similar patient and graft survival compared with those on cyclosporine-based therapy. There were also better metabolic and cardiovascular profiles associated with belatacept compared with cyclosporine therapy.
94. • Jo P, Grinyo JM, Vanrenterghem Y, et al. Three year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12(3):630-9. This study compared a traditional cyclosporine-based regimen with the new biologic agent beletacept in patients who had received extended criteria donor kidney transplants. They found that the belatecept group had a mean calculated GFR 11 ml/min higher than the cyclosporine treatment group at 3 years and that there was no increased risk of rejection.
95. • Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients. Transplantation. 2011;91(9):976-83. This study analyzed the data from the BENEFIT and BENEFIT-EXT studies specifically looking at cardiacvascular and metabolic endpoints. It was shown that at 12 months, the belatacept regimens were associated with lower blood pressure and lipid levels than the cyclosporine-based therapy. There was a lower incident of new-onset diabetes after transplant (NODAT) in the belatacept group.